BACKGROUND: The type 2 cytokines IL-4 and IL-13 promote not only atopic dermatitis (AD) but also the resolution of inflammation. How type 2 cytokines participate in the resolution of AD is poorly known. OBJECTIVE: Our aim was to determine the mechanisms and cell types governing skin inflammation, barrier dysfunction, and resolution of inflammation in a model of AD. METHODS: Mice that exhibit expression of IL-4, IL-13, and MCPT8 or that could be depleted of basophils or eosinophils, be deficient in IL-4 or MHC class II molecules, or have basophils lacking macrophage colony-stimulating factor (M-CSF) were treated with calcipotriol (MC903) as an acute model of AD. Kinetics of the disease; keratinocyte differentiation; and leukocyte accumulation, phenotype, function, and cytokine production were measured by transepidermal water loss, histopathology, molecular biology, or unbiased analysis of spectral flow cytometry. RESULTS: In this model of AD, basophils were activated systemically and were the initial and main source of IL-4 in the skin. Basophils and IL-4 promoted epidermal hyperplasia and skin barrier dysfunction by acting on keratinocyte differentiation during inflammation. Basophils, IL-4, and basophil-derived M-CSF inhibited the accumulation of proinflammatory cells in the skin while promoting the expansion and function of proresolution M2-like macrophages and the expression of probarrier genes. Basophils kept their proresolution properties during AD resolution. CONCLUSION: Basophils can display both beneficial and detrimental type 2 functions simultaneously during atopic inflammation.
BACKGROUND: The type 2 cytokines IL-4 and IL-13 promote not only atopic dermatitis (AD) but also the resolution of inflammation. How type 2 cytokines participate in the resolution of AD is poorly known. OBJECTIVE: Our aim was to determine the mechanisms and cell types governing skin inflammation, barrier dysfunction, and resolution of inflammation in a model of AD. METHODS: Mice that exhibit expression of IL-4, IL-13, and MCPT8 or that could be depleted of basophils or eosinophils, be deficient in IL-4 or MHC class II molecules, or have basophils lacking macrophage colony-stimulating factor (M-CSF) were treated with calcipotriol (MC903) as an acute model of AD. Kinetics of the disease; keratinocyte differentiation; and leukocyte accumulation, phenotype, function, and cytokine production were measured by transepidermal water loss, histopathology, molecular biology, or unbiased analysis of spectral flow cytometry. RESULTS: In this model of AD, basophils were activated systemically and were the initial and main source of IL-4 in the skin. Basophils and IL-4 promoted epidermal hyperplasia and skin barrier dysfunction by acting on keratinocyte differentiation during inflammation. Basophils, IL-4, and basophil-derived M-CSF inhibited the accumulation of proinflammatory cells in the skin while promoting the expansion and function of proresolution M2-like macrophages and the expression of probarrier genes. Basophils kept their proresolution properties during AD resolution. CONCLUSION: Basophils can display both beneficial and detrimental type 2 functions simultaneously during atopic inflammation.
Authors: J Hu-Li; C Pannetier; L Guo; M Löhning; H Gu; C Watson; M Assenmacher; A Radbruch; W E Paul Journal: Immunity Date: 2001-01 Impact factor: 31.745
Authors: Laura Ferrer-Font; Christophe Pellefigues; Johannes U Mayer; Sam J Small; Maria C Jaimes; Kylie M Price Journal: Curr Protoc Cytom Date: 2020-03
Authors: Brandon M Sullivan; Hong-Erh Liang; Jennifer K Bando; Davina Wu; Laurence E Cheng; James K McKerrow; Christopher D C Allen; Richard M Locksley Journal: Nat Immunol Date: 2011-05-08 Impact factor: 25.606
Authors: Ilkka S Junttila; Cynthia Watson; Laura Kummola; Xi Chen; Jane Hu-Li; Liying Guo; Ryoji Yagi; William E Paul Journal: J Allergy Clin Immunol Date: 2013-05-14 Impact factor: 10.793
Authors: Stephen J Jenkins; Dominik Ruckerl; Graham D Thomas; James P Hewitson; Sheelagh Duncan; Frank Brombacher; Rick M Maizels; David A Hume; Judith E Allen Journal: J Exp Med Date: 2013-10-07 Impact factor: 14.307
Authors: Lisa A Beck; Michael J Cork; Masayuki Amagai; Anna De Benedetto; Kenji Kabashima; Jennifer D Hamilton; Ana B Rossi Journal: JID Innov Date: 2022-04-26